
Christelle FerrÃ

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9370056/publications.pdf Version: 2024-02-01



CHDISTFILF FFDDÃ

#	Article	IF	CITATIONS
1	Leukocytapheresis variables and transit time for allogeneic cryopreserved hpc: better safe than sorry. Bone Marrow Transplantation, 2022, 57, 1531-1538.	1.3	5
2	Estudio prospectivo del seguimiento de pacientes largos supervivientes a un trasplante alogénico de progenitores hematopoyéticos. Medicina ClÃnica, 2021, 157, 281-284.	0.3	2
3	Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation. Annals of Hematology, 2021, 100, 541-553.	0.8	25
4	Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors. Bone Marrow Transplantation, 2021, 56, 992-996.	1.3	3
5	Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. Bone Marrow Transplantation, 2021, 56, 1919-1928.	1.3	13
6	Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplantation, 2021, 56, 2432-2444.	1.3	33
7	Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic?. Bone Marrow Transplantation, 2021, 56, 2489-2496.	1.3	15
8	Impact of risk scores in outcome of patients with myeloid neoplasms after allogeneic stem cell transplant. Medicina ClÃnica, 2021, , .	0.3	1
9	Gemtuzumab ozogamicina a bajas dosis en adultos con leucemia mieloide aguda. Medicina ClÃnica, 2021, 157, 325-328.	0.3	1
10	Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. Bone Marrow Transplantation, 2020, 55, 641-648.	1.3	58
11	Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2020, 26, 358-366.	2.0	36
12	Impact of previous admission to an intensive care unit on stem cell transplantation outcome. Medicina ClÃnica, 2020, 155, 382-387.	0.3	1
13	FMOD expression in whole blood aids in distinguishing between chronic lymphocytic leukemia and other leukemic lymphoproliferative disorders. A pilot study. Cytometry Part B - Clinical Cytometry, 2020, 98, 421-428.	0.7	9
14	Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis. Oncology and Therapy, 2020, 8, 311-324.	1.0	1
15	GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology.the. 2019. 6. e89-e99.	2.2	47
16	Changes in critically ill cancer patients' short-term outcome over the last decades: results of systematic review with meta-analysis on individual data. Intensive Care Medicine, 2019, 45, 977-987.	3.9	100
17	Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2019, 54, 1133-1137.	1.3	0
18	Enfermedad del injerto contra el receptor tras infección por Rickettsia conorii inducida por la picadura de una garrapata. Medicina ClÃnica, 2019, 152, 119-120.	0.3	0

Christelle FerrÃ

#	Article	IF	CITATIONS
19	Tratamiento de rescate de pacientes con leucemia aguda en recaÃda después de un primer trasplante alogénico de progenitores hematopoyéticos. Medicina ClÃnica, 2018, 151, 376-377.	0.3	0
20	Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions. Experimental Hematology, 2018, 62, 24-32.	0.2	15
21	Segundas neoplasias en pacientes adultos receptores de un trasplante de progenitores hematopoyéticos. Medicina ClÃnica, 2018, 150, 421-427.	0.3	0
22	Influence of neutropenia on mortality of critically ill cancer patients: results of a meta-analysis on individual data. Critical Care, 2018, 22, 326.	2.5	37
23	Utilidad del lavado broncoalveolar y la citometrÃa de flujo en pacientes con hemopatÃas malignas e insuficiencia respiratoria. Medicina ClÃnica, 2017, 148, 297-302.	0.3	0
24	Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma. Leukemia Research, 2017, 58, 98-101.	0.4	3
25	Monosomal karyotype in chronic lymphocytic leukemia: Association with clinical and biological features and potential prognostic significance. American Journal of Hematology, 2017, 92, E132-E135.	2.0	1
26	Relapse risk after autologous stem cell transplantation in patients with lymphoma based on CD34+ cell dose. Leukemia and Lymphoma, 2017, 58, 916-922.	0.6	5
27	Early and Long-Term Impaired T Lymphocyte Immune Reconstitution after Cord Blood Transplantation with Antithymocyte Clobulin. Biology of Blood and Marrow Transplantation, 2017, 23, 491-497.	2.0	37
28	Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia. Blood Advances, 2017, 1, 1047-1055.	2.5	6
29	Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of <i>TP53/ATM FISH</i> deletions. Oncotarget, 2017, 8, 54297-54303.	0.8	44
30	Cord Blood Units with High CD3 + Cell Counts Predict Early Lymphocyte Recovery After InÂVivo T Cell–Depleted Single Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1073-1079.	2.0	11
31	Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. New England Journal of Medicine, 2016, 374, 43-53.	13.9	436
32	Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico. Biology of Blood and Marrow Transplantation, 2016, 22, 584-588.	2.0	45
33	Impact of Refined Disease Risk Index after Single and Double Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies. Blood, 2016, 128, 3484-3484.	0.6	0
34	Few and Nonsevere Adverse Infusion Events Using an Automated Method for Diluting and Washing before Unrelated Single Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 682-687.	2.0	7
35	Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy. Brain, 2015, 138, 2847-2858.	3.7	128
36	Post-Thaw Viable CD45 + Cells and Clonogenic Efficiency areÂAssociated with Better Engraftment and Outcomes afterÂSingle Cord Blood Transplantation in Adult Patients withÂMalignant Diseases. Biology of Blood and Marrow Transplantation, 2015, 21, 2167-2172.	2.0	17

CHRISTELLE FERRÃ

#	Article	IF	CITATIONS
37	Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. Leukemia and Lymphoma, 2015, 56, 656-662.	0.6	32
38	Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica, 2014, 99, 378-384.	1.7	16
39	Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with highâ€dose melphalan for autologous stem cell transplantation for lymphoma and myeloma. European Journal of Haematology, 2014, 93, 487-491.	1.1	23
40	Mobilization and engraftment of peripheral blood stem cells in healthy related donors >55 years old. Cytotherapy, 2014, 16, 406-411.	0.3	13
41	Impact of Graft-versus-Host Disease Prophylaxis on Outcomes after Myeloablative Single-Unit Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1387-1392.	2.0	24
42	Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood, 2013, 122, 3951-3959.	0.6	55
43	Predictive factors for poor peripheral blood stem cell mobilization and peak CD34+cell count to guide pre-emptive or immediate rescue mobilization Cytotherapy, 2012, 14, 823-829.	0.3	50
44	Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results. British Journal of Haematology, 2012, 157, 67-74.	1.2	39
45	5.40 Rituximab Maintenance in Patients with Chronic Lymphocytic Leukemia after First-Line Treatment with Rituximab plus Fludarabine, Cyclophosphamide, and Mitoxantrone: Final Results of a Multicenter Phase II Trial on Behalf of the Spanish CLL Study Group (GELLC). Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S270-S272.	0.2	1
46	Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab. Expert Review of Hematology, 2011, 4, 9-16.	1.0	16
47	Unrelated Transplantation for Poor-Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Outcome Analysis and Study of the Impact of Hematopoietic Graft Source. Biology of Blood and Marrow Transplantation, 2010, 16, 957-966.	2.0	35
48	Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2009, 27, 4578-4584.	0.8	116
49	Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease: Results of a Phase II Study. Biology of Blood and Marrow Transplantation, 2009, 15, 639-642.	2.0	45
50	Antithymocyte globulin therapy for steroidâ€resistant acute graft versus host disease. American Journal of Hematology, 2008, 83, 824-825.	2.0	5
51	Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leukemia and Lymphoma, 2008, 49, 1752-1761.	0.6	98
52	Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival. Journal of Clinical Oncology, 2008, 26, 577-584.	0.8	213
53	Sirolimus as Part of Immunosuppressive Therapy for Refractory Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2007, 13, 701-706.	2.0	59
54	Outcome and Prognostic Factors in Patients with Hematologic Malignancies Admitted to the Intensive Care Unit: A Single-Center Experience. International Journal of Hematology, 2007, 85, 195-202.	0.7	59

CHRISTELLE FERRÃ

#	Article	IF	CITATIONS
55	Systemic thrombotic thrombocytopenic purpura (TTP) following unrelated cord blood transplantation. Leukemia and Lymphoma, 2006, 47, 1173-1175.	0.6	1
56	A case of non-lethal pulmonary air embolism after leukapheresis catheter removal. Journal of Clinical Apheresis, 2005, 20, 93-94.	0.7	2
57	Mixed chimerism is frequent after allogeneic peripheral blood stem cell transplantation with positive CD34 selection, and is not reverted by low doses of donor T-cells add-back. European Journal of Haematology, 2004, 73, 162-168.	1.1	4
58	Positive selection for CD34 + reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Experimental Hematology, 2003, 31, 545-550.	0.2	31
59	Outcome and Toxicity of Salvage Treatment in Patients Relapsing After Autologous Hematopoietic Stem Cell TransplantationExperience from a Single Center. Hematology, 2003, 8, 145-150.	0.7	3
60	Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood, 2002, 100, 724-727.	0.6	68
61	Autologous stem cell transplantation and purging in adult acute lymphoblastic leukaemia. Best Practice and Research in Clinical Haematology, 2002, 15, 675-693.	0.7	6
62	Long-Term disease-free survival in a primary plasma cell leukemia treated by VAD, autologous PBSC transplantation, and IFN-α. American Journal of Hematology, 2002, 71, 62-62.	2.0	4
63	A relapsed non-Hodgkin lymphoma presenting as panhypopituitarism successfully treated by chemotherapy. Journal of Neuro-Oncology, 2002, 59, 35-38.	1.4	9
64	Lack of impact of human immunodeficiency virus infection on the outcome of lymphoma patients transferred to the intensive care unit. Leukemia and Lymphoma, 0, , 425-430.	0.6	2
65	Post thawing viable CD34+ Cells dose is a better predictor of clinical outcome in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplantation, 0, , .	1.3	2
66	Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. Bone Marrow Transplantation, 0, , .	1.3	1